Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
Analyzing the Growth Rate of the Nephrotic Syndrome Market: What’s the Expected CAGR for the Next Decade?
The market size for nephrotic syndrome has seen significant growth recently. The market size will elevate from a valuation of $0.87 billion in 2024 to about $00.96 billion in 2025, with a compound annual growth rate (CAGR) of 11.0%. The historical growth of this market can be traced back to factors such as rising incidences of nephrotic syndrome, increased genetic disorder cases, growing obesity rates, more usage of immunosuppressive medications, and the escalating influence of genetic elements.
The market size for nephrotic syndrome is predicted to experience substantial growth in the coming years, escalating to $1.44 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 10.7%. This anticipated growth within the forecast period can be credited to the increase in awareness of Nephrotic Syndrome, a surge in the prevalence of CKD, a rising occurrence of metabolic disorders, an expanding aging population, and a growing prevalence of autoimmune diseases. Some prominent trends expected during the forecast period incorporate telemedicine and remote monitoring, the introduction of novel drug delivery systems, advancement in treatment methods, development in biotechnology, and the implementation of digital health technologies.
What Combination of Drivers Is Leading to Accelerated Growth in the Nephrotic Syndrome Market?
The escalating prevalence of ailments related to kidneys is anticipated to accelerate the expansion of the nephrotic syndrome market in the future. Kidney disease encompasses any maladies or disorders that damage the role of the kidneys, which are invaluable organs responsible for purging the blood of waste and additional fluids. The rising frequency of kidney maladies can be traced back to elements such as diabetes, hypertension, overweight, the aging demographic, and modifications in lifestyle, including high salt consumption and insufficient hydration. The nephrotic syndrome amplifies kidney diseases by inflicting harm to the glomeruli, thereby compromising the kidney’s capacity to sift out waste while retaining vital proteins. For example, in June 2024, as per the Australian Institute of Health and Welfare, an organization run by the Australian government, the death rate from chronic kidney diseases (CKD) surged from 4.2% in 2021 to 6.2% in 2022 in Australia. Consequently, the escalating prevalence of kidney diseases is propelling the expansion of the nephrotic syndrome market.
Request Your Free Nephrotic Syndrome Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21228&type=smp
What are the leading organizations impacting the Nephrotic Syndrome market’s growth?
Major companies operating in the nephrotic syndrome market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Eli Lilly and Company, Asahi Kasei Corporation, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals, Chugai Pharmaceutical Co. Ltd., Mallinckrodt Company, Evotec SE, Travere Therapeutics Inc., Aurinia Pharmaceuticals Inc., Orbis Biosciences Inc., Alpine Immune Sciences, Kezar Life Sciences, Zenyaku Kogyo Co. Ltd
What Are the Most Prominent Trends Driving Change in the Nephrotic Syndrome Market?
Recognized firms in the nephrotic syndrome market are centring their efforts on creating novel treatment options such as loop diuretic injections, with an aim to enhance fluid management and mitigate edema in patients suffering from nephrotic syndrome. Loop diuretic injections are composed of drugs that impede the reabsorption of sodium and chloride in the loop of Henle, leading to accelerated urine production. They are essential in the treatment of ailments like acute pulmonary edema, heart failure, and severe hypertension as they aid in reducing fluid excess. As an example, Avenacy Inc., a pharmaceutical firm based in the US, introduced a generic equivalent to Lasix called furosemide for injection in the U.S. in March 2024. This was approved by the Food and Drug Administration for treating edema linked to heart failure, liver cirrhosis, and kidney disorders. This drug, which is available in 25-unit packs of 100 mg/10 mL doses, forms part of Avenacy’s extensive strategy to broaden its injectable medication portfolio and plans to launch over 20 products in 2024. Both adults and children can be prescribed this drug for the alleviation of edema associated with congestive heart failure, liver cirrhosis, and kidney diseases including nephrotic syndrome.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/nephrotic-syndrome-global-market-report
What Are the Core Segments of the Nephrotic Syndrome Market, and How Do They Contribute to Growth?
The nephrotic syndrome market covered in this report is segmented –
1) By Type: Drugs, Devices
2) By Diagnosis Tests: Urinalysis, Glomerular Filtration Rate (GFR), Blood Test, Kidney Biopsy, Computerized Tomography (CT) Scan
3) By Application: Clinics, Hospitals, Speciality Centres, Other Applications
Subsegments:
1) By Drugs: Steroids, Immunosuppressants, Diuretics, ACE Inhibitors Or ARBs, Other Drugs
2) By Devices: Dialysis Machines, Peritoneal Dialysis Catheters, Hemodialysis Catheters, Kidney Replacement Therapy Devices
What Regions Are Leading the Charge in the Nephrotic Syndrome Market?
North America was the largest region in the nephrotic syndrome market in 2024. The regions covered in the nephrotic syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Nephrotic Syndrome Market Categorized and Defined in the Industry?
Nephrotic syndrome is a kidney disorder characterized by excessive protein loss in the urine (proteinuria), low levels of protein in the blood (hypoalbuminemia), high cholesterol levels (hyperlipidemia), and swelling (edema), especially in the legs, feet, and around the eyes. It occurs due to damage to the glomeruli, the kidney’s filtering units, which allows the protein to leak into the urine.
Browse Through More Similar Reports By The Business Research Company:
Hepatitis B Virus (HBV) Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Viral Hepatitis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report
Global Genetic Testing Global Market Report 2025
https://thebusinessresearchcompany.com/report/genetic-testing-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: